These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

785 related items for PubMed ID: 19581278

  • 1. Anti-infliximab and anti-adalimumab antibodies in relation to response to adalimumab in infliximab switchers and anti-tumour necrosis factor naive patients: a cohort study.
    Bartelds GM, Wijbrandts CA, Nurmohamed MT, Stapel S, Lems WF, Aarden L, Dijkmans BA, Tak PP, Wolbink GJ.
    Ann Rheum Dis; 2010 May; 69(5):817-21. PubMed ID: 19581278
    [Abstract] [Full Text] [Related]

  • 2. The presence or absence of antibodies to infliximab or adalimumab determines the outcome of switching to etanercept.
    Jamnitski A, Bartelds GM, Nurmohamed MT, van Schouwenburg PA, van Schaardenburg D, Stapel SO, Dijkmans BA, Aarden L, Wolbink GJ.
    Ann Rheum Dis; 2011 Feb; 70(2):284-8. PubMed ID: 21068090
    [Abstract] [Full Text] [Related]

  • 3. Do rheumatoid arthritis patients in clinical practice benefit from switching from infliximab to a second tumor necrosis factor alpha inhibitor?
    Hjardem E, Østergaard M, Pødenphant J, Tarp U, Andersen LS, Bing J, Peen E, Lindegaard HM, Ringsdal VS, Rødgaard A, Skøt J, Hansen A, Mogensen HH, Unkerskov J, Hetland ML.
    Ann Rheum Dis; 2007 Sep; 66(9):1184-9. PubMed ID: 17389656
    [Abstract] [Full Text] [Related]

  • 4. Adalimumab (Humira) restores clinical response in patients with secondary loss of efficacy from infliximab (Remicade) or etanercept (Enbrel): results from the STURE registry at Karolinska University Hospital.
    Wick MC, Ernestam S, Lindblad S, Bratt J, Klareskog L, van Vollenhoven RF.
    Scand J Rheumatol; 2005 Sep; 34(5):353-8. PubMed ID: 16234182
    [Abstract] [Full Text] [Related]

  • 5. Effectiveness of adalimumab for rheumatoid arthritis in patients with a history of TNF-antagonist therapy in clinical practice.
    Bombardieri S, Ruiz AA, Fardellone P, Geusens P, McKenna F, Unnebrink K, Oezer U, Kary S, Kupper H, Burmester GR, Research in Active Rheumatoid Arthritis (ReAct) Study Group.
    Rheumatology (Oxford); 2007 Jul; 46(7):1191-9. PubMed ID: 17504821
    [Abstract] [Full Text] [Related]

  • 6. Efficacy and safety of switching from infliximab to adalimumab: a comparative controlled study.
    Nikas SN, Voulgari PV, Alamanos Y, Papadopoulos CG, Venetsanopoulou AI, Georgiadis AN, Drosos AA.
    Ann Rheum Dis; 2006 Feb; 65(2):257-60. PubMed ID: 15975964
    [Abstract] [Full Text] [Related]

  • 7. Anti-Ro/SSA antibodies are an independent factor associated with an insufficient response to tumor necrosis factor inhibitors in patients with rheumatoid arthritis.
    Matsudaira R, Tamura N, Sekiya F, Ogasawara M, Yamanaka K, Takasaki Y.
    J Rheumatol; 2011 Nov; 38(11):2346-54. PubMed ID: 21965648
    [Abstract] [Full Text] [Related]

  • 8. Treatment response to a second or third TNF-inhibitor in RA: results from the South Swedish Arthritis Treatment Group Register.
    Karlsson JA, Kristensen LE, Kapetanovic MC, Gülfe A, Saxne T, Geborek P.
    Rheumatology (Oxford); 2008 Apr; 47(4):507-13. PubMed ID: 18304941
    [Abstract] [Full Text] [Related]

  • 9. Effectiveness, predictive response factors, and safety of anti-tumor necrosis factor (TNF) therapies in anti-TNF-naive rheumatoid arthritis.
    Fernández-Nebro A, Irigoyen MV, Ureña I, Belmonte-López MA, Coret V, Jiménez-Núñez FG, Díaz-Cordovés G, López-Lasanta MA, Ponce A, Rodríguez-Pérez M, Calero E, González-Santos P.
    J Rheumatol; 2007 Dec; 34(12):2334-42. PubMed ID: 17985409
    [Abstract] [Full Text] [Related]

  • 10. A comparative effectiveness study of adalimumab, etanercept and infliximab in biologically naive and switched rheumatoid arthritis patients: results from the US CORRONA registry.
    Greenberg JD, Reed G, Decktor D, Harrold L, Furst D, Gibofsky A, Dehoratius R, Kishimoto M, Kremer JM, CORRONA Investigators.
    Ann Rheum Dis; 2012 Jul; 71(7):1134-42. PubMed ID: 22294625
    [Abstract] [Full Text] [Related]

  • 11. Adalimumab in clinical practice. Outcome in 70 rheumatoid arthritis patients, including comparison of patients with and without previous anti-TNF exposure.
    Bennett AN, Peterson P, Zain A, Grumley J, Panayi G, Kirkham B.
    Rheumatology (Oxford); 2005 Aug; 44(8):1026-31. PubMed ID: 15870150
    [Abstract] [Full Text] [Related]

  • 12. B cell depletion may be more effective than switching to an alternative anti-tumor necrosis factor agent in rheumatoid arthritis patients with inadequate response to anti-tumor necrosis factor agents.
    Finckh A, Ciurea A, Brulhart L, Kyburz D, Möller B, Dehler S, Revaz S, Dudler J, Gabay C, Physicians of the Swiss Clinical Quality Management Program for Rheumatoid Arthritis.
    Arthritis Rheum; 2007 May; 56(5):1417-23. PubMed ID: 17469098
    [Abstract] [Full Text] [Related]

  • 13. Which factors influence radiographic progression during treatment with tumor necrosis factor inhibitors in clinical practice? Results from 930 patients with rheumatoid arthritis in the nationwide Danish DANBIO registry.
    Ørnbjerg LM, Østergaard M, Bøyesen P, Krogh NS, Thormann A, Tarp U, Poulsen UE, Espesen J, Schlemmer A, Graudal N, Kollerup G, Jensen DV, Madsen OR, Glintborg B, Christensen T, Lindegaard H, Bøhme W, Hansen A, Andersen AR, Hetland ML.
    J Rheumatol; 2014 Dec; 41(12):2352-60. PubMed ID: 25274894
    [Abstract] [Full Text] [Related]

  • 14. Association between anti-tumour necrosis factor treatment response and genetic variants within the TLR and NF{kappa}B signalling pathways.
    Potter C, Cordell HJ, Barton A, Daly AK, Hyrich KL, Mann DA, Morgan AW, Wilson AG, Biologics in Rheumatoid Arthritis Genetics and Genomics Study Syndicate (BRAGGSS), Isaacs JD.
    Ann Rheum Dis; 2010 Jul; 69(7):1315-20. PubMed ID: 20448286
    [Abstract] [Full Text] [Related]

  • 15. Differences in annual medication costs and rates of dosage increase between tumor necrosis factor-antagonist therapies for rheumatoid arthritis in a managed care population.
    Ollendorf DA, Klingman D, Hazard E, Ray S.
    Clin Ther; 2009 Apr; 31(4):825-35. PubMed ID: 19446156
    [Abstract] [Full Text] [Related]

  • 16. Formation of antibodies against infliximab and adalimumab strongly correlates with functional drug levels and clinical responses in rheumatoid arthritis.
    Radstake TR, Svenson M, Eijsbouts AM, van den Hoogen FH, Enevold C, van Riel PL, Bendtzen K.
    Ann Rheum Dis; 2009 Nov; 68(11):1739-45. PubMed ID: 19019895
    [Abstract] [Full Text] [Related]

  • 17. Persistent periodontal disease hampers anti-tumor necrosis factor treatment response in rheumatoid arthritis.
    Savioli C, Ribeiro AC, Fabri GM, Calich AL, Carvalho J, Silva CA, Viana VS, Bonfá E, Siqueira JT.
    J Clin Rheumatol; 2012 Jun; 18(4):180-4. PubMed ID: 22647860
    [Abstract] [Full Text] [Related]

  • 18. Persistence with anti-tumor necrosis factor therapies in patients with rheumatoid arthritis: observations from the RADIUS registry.
    Markenson JA, Gibofsky A, Palmer WR, Keystone EC, Schiff MH, Feng J, Baumgartner SW.
    J Rheumatol; 2011 Jul; 38(7):1273-81. PubMed ID: 21572150
    [Abstract] [Full Text] [Related]

  • 19. Effectiveness of switching between TNF inhibitors in ankylosing spondylitis: data from the NOR-DMARD register.
    Lie E, van der Heijde D, Uhlig T, Mikkelsen K, Rødevand E, Koldingsnes W, Kaufmann C, Kvien TK.
    Ann Rheum Dis; 2011 Jan; 70(1):157-63. PubMed ID: 21062852
    [Abstract] [Full Text] [Related]

  • 20. Direct comparison of treatment responses, remission rates, and drug adherence in patients with rheumatoid arthritis treated with adalimumab, etanercept, or infliximab: results from eight years of surveillance of clinical practice in the nationwide Danish DANBIO registry.
    Hetland ML, Christensen IJ, Tarp U, Dreyer L, Hansen A, Hansen IT, Kollerup G, Linde L, Lindegaard HM, Poulsen UE, Schlemmer A, Jensen DV, Jensen S, Hostenkamp G, Østergaard M, All Departments of Rheumatology in Denmark.
    Arthritis Rheum; 2010 Jan; 62(1):22-32. PubMed ID: 20039405
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 40.